AK HB215

Physicians are protected from disciplinary action when prescribing, dispensing, or administering investigational drugs, biological products, or devices to terminally ill patients who have considered FDA-approved alternatives and provided written informed consent.

"Investigational" drugs must have completed Phase 1 clinical trials but lack FDA approval for general use; "terminal illness" means a disease resulting in near-future death or permanent unconsciousness without life-sustaining procedures.

Hospitals and health facilities are prohibited from restricting or forbidding use of investigational drugs when prescribed by physicians under this law.

Physicians, manufacturers, importers, and distributors of investigational drugs are granted immunity from liability for patient injury or death if acting in good faith with reasonable care and providing written notice of immunity protections.

Exempts physicians complying with this law from requirements under AS 17.20.110 regarding new drug prescriptions.